It can be hard to sate investors’ appetites, but if there’s two companies who should know how to do it, it’s these two.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
Traditionally, New Year’s resolutions to lose weight involve getting to the gym more. In a post-GLP-1 world, that’s looking less necessary.
A new study suggests increasingly popular GLP-1 drugs could help cut opioid and alcohol abuse nearly in half.
New estimates say that Medicare will spend tens of billions of dollars over nine years to cover weight-loss drugs.
Obesity drugmaker Rivus is working with banks to complete a US public listing that could happen before the end of the year.